Moderna and Merck Milestone Triggers Record Stock Rally for mRNA Cancer Therapy

By Natasha Etzel · Fast Company · 2026-08-19

Fast Company reports that Moderna shares surged over 120% following successful Phase 3 trial results for a personalized melanoma vaccine developed alongside Merck. The treatment, which combines mRNA technology with the drug Keytruda, reached its primary goal of lowering cancer re

Fast Company reports that Moderna shares surged over 120% following successful Phase 3 trial results for a personalized melanoma vaccine developed alongside Merck. The treatment, which combines mRNA technology with the drug Keytruda, reached its primary goal of lowering cancer re